IP Library › Granted Patent US 9,272,052
Granted Patent B2
US 9,272,052 · App. 13/879,012 · Granted Mar 1, 2016

Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,052
App. No.
13/879,012
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.

Claims (2)

1. A method for treating Hodgkin lymphoma or anaplastic large cell lymphoma in a subject in need thereof, comprising administering to the subject an auristatin-based antibody drug conjugate that binds CD30 and a rapalog inhibitor of the PI3K-AKT-mTOR pathway.

2. The method of claim 1 , wherein the antibody drug conjugate is brentuximab vedotin and the rapalog inhibit is temsirolimus, sirolimus, or everolimus.

Assignments (2)
CHANGE OF NAME Recorded Feb 18, 2021
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 055334/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2013
From: LEWIS, TIMOTHY S.; LAW, CHE-LEUNG; MCEARCHERN, JULIE A.
To: SEATTLE GENETICS, INC.
Reel/Frame 030334/0694 →